Thorac Cardiovasc Surg 2021; 69(01): 101-108
DOI: 10.1055/s-0039-1695784
Original Thoracic

Surgical Outcomes and Risk Analysis of Primary Pulmonary Sarcoma

Yoshito Yamada
1   Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
2   Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
,
Tevfik Kaplan
3   Department of Thoracic Surgery, Ufuk University School of Medicine, Ankara, Çankaya, Turkey
,
Alex Soltermann
4   Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
,
Isabelle Schmitt-Opitz
1   Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
,
Didier Schneiter
1   Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
,
Walter Weder
1   Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
,
Ilhan Inci
1   Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
› Author Affiliations

Abstract

Background Primary pulmonary sarcoma (PPS) is a rare malignant lung neoplasm, and there is very little medical evidence about treatment of PPS. The aim of this study is to clarify the clinical characteristics and therapeutic outcome of patients who underwent surgical resection for PPS.

Methods We retrospectively reviewed the records of patients who underwent surgical resection for PPS in our institution between 1995 and 2014. Cases who only underwent biopsy were excluded.

Results A total of 24 patients (18 males, 6 females), with a median age of 60 (interquartile range: 44–67) years, were analyzed. The surgical procedures performed in these patients were pneumonectomy (n = 10), lobectomy (n = 11), and wedge resection (n = 3). Complete resection was achieved in 16 patients. The pathological stages (tumor, node, metastases lung cancer classification, 8th edition) of the patients were I (n = 4), II (n = 12), III (n = 2), and IV (n = 5), and there were four cases of lymph node metastasis. The 5-year overall survival rate of the patients was 50% (95% confidence interval [CI]: 29–72). Adverse prognostic factors for overall survival were incomplete resection (hazard ratio [HR]: 4.4, 95% CI: 2.1–42), advanced pathological stage (HR 14, 95% CI: 2.8–66), higher pathological grade (HR 4.5, 95% CI: 1.2–17), and tumor size ≥ 7 cm (HR 4.7, 95% CI: 1.1–21).

Conclusions Our series of PPS revealed that incomplete resection, advanced pathological stage, higher pathological grade, and tumor size were unfavorable factors for long-term survival.



Publication History

Received: 08 May 2019

Accepted: 22 July 2019

Article published online:
09 September 2019

© 2019. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75 (1, Suppl): 191-202
  • 2 Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010; 2010: 506182
  • 3 Tan MC, Brennan MF, Kuk D. et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg 2016; 263 (03) 593-600
  • 4 Janssen JP, Mulder JJ, Wagenaar SS, Elbers HR, van den Bosch JM. Primary sarcoma of the lung: a clinical study with long-term follow-up. Ann Thorac Surg 1994; 58 (04) 1151-1155
  • 5 Bacha EA, Wright CD, Grillo HC. et al. Surgical treatment of primary pulmonary sarcomas. Eur J Cardiothorac Surg 1999; 15 (04) 456-460
  • 6 Régnard JF, Icard P, Guibert L, de Montpreville VT, Magdeleinat P, Levasseur P. Prognostic factors and results after surgical treatment of primary sarcomas of the lung. Ann Thorac Surg 1999; 68 (01) 227-231
  • 7 Porte HL, Metois DG, Leroy X, Conti M, Gosselin B, Wurtz A. Surgical treatment of primary sarcoma of the lung. Eur J Cardiothorac Surg 2000; 18 (02) 136-142
  • 8 Etienne-Mastroianni B, Falchero L, Chalabreysse L. et al. Primary sarcomas of the lung: a clinicopathologic study of 12 cases. Lung Cancer 2002; 38 (03) 283-289
  • 9 Petrov DB, Vlassov VI, Kalaydjiev GT. et al. Primary pulmonary sarcomas and carcinosarcomas--postoperative results and comparative survival analysis. Eur J Cardiothorac Surg 2003; 23 (04) 461-466
  • 10 Spraker MB, Bair E, Bair R, Connell PP, Mahmood U, Koshy M. An analysis of patient characteristics and clinical outcomes in primary pulmonary sarcoma. J Thorac Oncol 2013; 8 (02) 147-151
  • 11 IARC. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013
  • 12 Tomashefski JF, Dacic S, Aubry MC. et al. Mesenchymal tumours. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th edition. Geneva: IARC Press; 2015
  • 13 Rami-Porta R, Ball D, Crowley J. et al; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2 (07) 593-602
  • 14 McCormack PM, Matini N. Primary sarcomas and lymphomas of the lung. In: Matini N, Vogt-Moykopf I. eds. Thoracic Surgery: Frontiers and Uncommon Neoplasms Vol5. St. Louis: CV Mosby; 1989: 261-283
  • 15 Pennacchioli E, Tosti G, Barberis M. et al. Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?. Clin Exp Metastasis 2012; 29 (07) 757-773
  • 16 Attanoos RL, Appleton MA, Gibbs AR. Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases. Histopathology 1996; 29 (01) 29-36
  • 17 Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 2014; 83 (02) 240-245
  • 18 Yamada Y, Yoshino I, Nakajima J. et al; Japanese Association for Research of the Thymus. Surgical outcomes of patients with stage iii thymoma in the Japanese nationwide database. Ann Thorac Surg 2015; 100 (03) 961-967
  • 19 Nakano K, Takahashi S. Current molecular targeted therapies for bone and soft tissue sarcomas. Int J Mol Sci 2018; 19 (03) 19
  • 20 Yen CC, Chen TW. Next frontiers in systemic therapy for soft tissue sarcoma. Linchuang Zhongliuxue Zazhi 2018; 7 (04) 43
  • 21 Wu YC, Wang LS, Chen W, Fahn HJ, Huang MH, Whang-Peng J. Primary pulmonary malignant hemangiopericytoma associated with coagulopathy. Ann Thorac Surg 1997; 64 (03) 841-843
  • 22 Inci I, Soltermann A, Schneiter D, Weder W. Pulmonary malignant peripheral nerve sheath tumour. Eur J Cardiothorac Surg 2014; 46 (02) 331-332
  • 23 Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975; 1 (01) 63-76
  • 24 Borden EC, Amato DA, Rosenbaum C. et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5 (06) 840-850
  • 25 Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol 2019; 20 (01) 6
  • 26 Patel SR, Vadhan-Raj S, Papadopolous N. et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol 1997; 15 (06) 2378-2384
  • 27 Judson I, Verweij J, Gelderblom H. et al; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15 (04) 415-423
  • 28 Tap WD, Jones RL, Van Tine BA. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016; 388 (10043): 488-497
  • 29 [Anonymous] . Olaratumab for STS Disappoints in Phase III. Cancer Discov 2019; 9 (03) 312-313
  • 30 Zobniw CM, Trinh VA, Posey K, Somaiah N. Olaratumab in the management of advanced soft tissue sarcoma. J Oncol Pharm Pract 2019; 25 (02) 442-448
  • 31 Veenstra R, Kostine M, Cleton-Jansen AM, de Miranda NF, Bovée JV. Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. Lab Invest 2018; 98 (01) 41-50
  • 32 Kim JR, Moon YJ, Kwon KS. et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 2013; 8 (12) e82870
  • 33 Tawbi HA, Burgess M, Bolejack V. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18 (11) 1493-1501
  • 34 Groisberg R, Hong DS, Behrang A. et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 2017; 5 (01) 100
  • 35 Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas. Oncologist 2018; 23 (01) 71-83
  • 36 Wilky BA, Trucco MM, Subhawong TK. et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol 2019; 20 (06) 837-848